Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Magenta Investments, a leading pharmaceutical and healthcare company that is part of an investment and industrial conglomerate in the United Arab Emirates (UAE), today announced a new agreement to distribute the Moderna COVID-19 Vaccine as well as Moderna’s updated variant booster candidates, once authorized, in the UAE in 2021 and 2022.
“We welcome the opportunity to work alongside Magenta for the distribution of our vaccine in the UAE”
“We welcome the opportunity to work alongside Magenta for the distribution of our vaccine in the UAE,” said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna. “Together with our partners, we hope to advance our goal to expand access to our vaccine globally, and support governments such as the UAE in protecting their citizens, residents and visitors against the pandemic.”
Marketing Technology News: Jellysmack Steps Into The Cage: The Global Creator Company Launches Its Media Partner Program With…
“As the world continues to endure the drastic impact of the COVID-19 pandemic, we feel privileged to be taking part in the global effort to enhance the protection of humanity by making available this highly advanced vaccine in the United Arab Emirates. Magenta is fully committed to supporting the efforts of the government of the United Arab Emirates in its monumental efforts to contain the pandemic,” said Dr. Zahid Al Sabti, Managing Director of Magenta Investments. “I am delighted to see Magenta entering this strategic partnership with Moderna and contributing to the ongoing battle against the pandemic.”
Comments are closed.